<DOC>
	<DOCNO>NCT02284035</DOCNO>
	<brief_summary>A pilot 24-week open-label , randomize , control clinical trial ass safety , tolerability efficacy dual therapy Raltegravir/Lamivudine combination replace standard combination therapy HIV-infected patient prolonged virological suppression</brief_summary>
	<brief_title>Safety &amp; Efficacy Dual Therapy With Raltegravir/Lamivudine</brief_title>
	<detailed_description />
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Eligible patient male female least 18 year age . Women childbearing potential must negative pregnancy test within 10 day prior randomization study . 2 . Patients seropositive HIV1 use standard diagnostic criterion . 3 . Patients virologically suppress least 12 month prior inclusion ( viral load &lt; 50 copies/mL ) . 4 . Patients combination antiretroviral therapy ( least 2 antiretroviral drug ) least 12 month randomize study . 5 . Patients clinically stable opinion investigator study entry ( clinical status chronic medication must modify least 14 day prior randomization ) . 6 . Patients sign informed consent participate study . 1 . Pregnancy , lactation , plan pregnancy study period . 2 . Previous failure integrase inhibitorcontaining regimen . 3 . Previous failure 3TC FTCcontaining regimen . 4 . Resistance mutation 3TC integrase inhibitor resistance test previously perform . 5 . Any disease history disease , opinion investigator , might confound result study pose additional risk patient treatment . 6 . Chronic hepatitis B .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>